The first of five scheduled clinical trials for medicinal herbal wine will start in November, with another scheduled for February 2019.
It is the first trial of a medicinal herb for a specific ailment, and could pave the way for the first trials of medicinal cannabis for chronic pain and cancer, which are not yet approved.
“We’re not doing this for recreational purposes,” said Dr John Turetsky, head of the division of pharmaceutical and medical toxicology at the Royal College of Physicians.
The other two trials are focused on how it might be administered to patients who have suffered from a particular condition, and to see if it’s safe to give to patients.””
This will be the first time a medicine has been specifically approved for use in a specific condition.”
The other two trials are focused on how it might be administered to patients who have suffered from a particular condition, and to see if it’s safe to give to patients.
“If we’re going to be able to prove the efficacy of this in the long term, we need to see it in a real-world setting.”
The trials are part of a broader effort by the Medicines for Humanitarian Relief Foundation (MHF), which also plans to launch an investigatoin trial of medicinal marijuana in 2019, in the hopes of finding out whether the drug is safe and effective.
The MHF says it hopes to get approval from the Medicinal Drug Advisory Committee (MDC), the US Food and Drug Administration (FDA), and the UK’s National Institute for Health Research (NICE), as well as other regulatory bodies, by the end of the year.
Dr Turetsko said: “We are very hopeful that this drug will be approved.
We are also very optimistic that it will be a safe drug.”
It is still very early days and we have a long way to go before this drug can be prescribed for chronic conditions like this.
“The MDC, which is in charge of approving medicines for the NHS, will decide whether medicinal cannabis should be prescribed.
If the MDC approves the medicinal cannabis, it would be a major step forward for the pharmaceutical industry.
Last year, the MFC said it would make a final decision on the medicinal use of marijuana by March 2020.
In April, the MHF announced plans to invest £2 million to study the use of cannabis for a range of conditions.
The organisation has already published research findings on the potential benefits of medicinal pot for chronic illness, and says it has found the drug works for chronic epilepsy.”
The first clinical trial of the medicinal herb will start the month of November, but it is not clear whether the trials will last longer.””
We need to be prepared for a decision.”
The first clinical trial of the medicinal herb will start the month of November, but it is not clear whether the trials will last longer.
“There are many trials, but they are just getting started, so we are waiting for the MMC to make a ruling,” said Rolf Schulz, a medical toxicologist and professor at the University of Gothenburg.
“They can also make a statement at a later date.
It’s important for us to get this going quickly.”
Dr Turedtsky said that in the interim, it was crucial to get a grip on the supply chain, with some countries having to import medicinal herbs from China.
“When we do this trial, we are going to start with Chinese herbs and work our way through to other countries,” he said.
“But in the meantime, we will be looking at other sources.”
The MHf said that it expected to get the first batches of medicinal herbs, which will be shipped out of the UK and Europe, in October, but the final batches will be available for sale in Europe.
“These are going in from the United States and Canada, so this will be an interesting first phase of this trial,” said a spokesman.
“Other countries will also have a chance to have a look at this trial and get an opinion from the MHM.”
The medicines are being developed in collaboration with UK pharmaceutical company GSK, which has developed a cannabis oil called Cannabidiol (CBD).
The MHF said it was committed to bringing its medicinal cannabis to market, but also said it wanted to be sure that the trials went smoothly.
“This is a great first step towards making the medical cannabis a reality,” said Paul Williams, MHF chief executive.
“GSK has shown great leadership in the industry, but we need the UK Government to take a lead.”
CBD, a natural cannabinoid produced in hemp, is a natural alternative to opiates, which have been shown to be addictive, and has shown to offer a safe, effective and long-term treatment option for severe chronic pain.